Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
Future Oncol
; 14(9): 891-895, 2018 Apr.
Article
en En
| MEDLINE
| ID: mdl-29527939
ABSTRACT
AIM:
To determine which of the CDK4/6 inhibitors is the optimal treatment in metastatic luminal breast cancer. MATERIALS &METHODS:
A network meta-analysis using the frequentist approach and generalized pairwise modeling was computed.RESULTS:
The associations of aromatase inhibitor with ribociclib, palbociclib and abemaciclib were similar in efficacy. Palbociclib-based regimen was associated with significantly lower treatment discontinuation rates compared with the other approved drugs in this indication.CONCLUSION:
In the absence of direct comparative evidence, the results of this network meta-analysis represent the best available evidence for decision making in the first-line treatment of metastatic luminal breast cancer.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piperazinas
/
Purinas
/
Piridinas
/
Bencimidazoles
/
Neoplasias de la Mama
/
Aminopiridinas
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Female
/
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2018
Tipo del documento:
Article
País de afiliación:
Líbano